ArticleAmerican journal of translational research2021
Correlation of aspirin resistance with serological indicators in patients with coronary heart disease in the plateau.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the incidence rate of aspirin resistance (AR) in patients with coronary heart disease (CHD) in the plateau, and analyze its correlation with clinical influencing factors and serological indicators.
methodsIn this retrospective study, 90 patients with CHD who had lived in the plateau for a long time (>10 years) and received treatment were selected as the subjects. Patients were divided into the AR group (11-dehydrothromboxane B2 (11-DH-TXB
resultsThe incidence rate of AR in the enrolled patients with CHD was 27.78% (25/90). The body mass index (BMI) in the AR group was significantly higher than that in the AS group (P<0.05). Patients in the AR group had significantly higher C-reactive protein (CRP) and total bilirubin levels and lower mean corpuscular volume and mean corpuscular hemoglobin compared with the AS group (all P<0.05). Binary logistic regression showed that BMI and CRP were independent factors for AR.
conclusionAR occurs in patients with CHD who take aspirin in the plateau. Patients with high BMI or CRP level have an increased risk of AR. In addition, BMI and CRP are independent factors for AR, and bilirubin can be a predictive factor for AR.
Indexed as
Identifiers
34540014PMC8430094W3200508920What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.